跳至主要内容
临床试验/NCT00000179
NCT00000179已完成3 期

Agitation in Alzheimer's Disease

National Institute on Aging (NIA)30 个研究点 分布在 1 个国家开始时间: 1999年11月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
试验地点
30

研究概览

简要总结

Agitation affects 70 to 90 percent of patients with AD. Signs of agitation include verbal and physical aggressiveness, irritability, wandering, and restlessness. These behaviors often make caring for patients at home very difficult. Trazodone and haldol are two of the most commonly prescribed drugs for agitation in AD patients. Behavior management, a non drug approach, has been effective in reducing signs of agitation. Researchers have yet to compare the effectiveness of drug versus non drug therapy to treat agitation in AD patients and determine which is the best treatment. The Alzheimer's Disease Cooperative Study, with funding from the National Institute on Aging, is conducting an agitation treatment program at 21 sites in 16 States. This study will assess which of the above treatments is most effective.

研究设计

研究类型
Interventional
分配方式
Randomized
主要目的
Treatment
盲法
Double

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Memory problem consistent with a probable diagnosis of Alzheimer's disease (AD)
  • Agitation symptoms for at least the past 2 weeks
  • Patient has caregiver who can participate
  • Patient lives in the same household as the caregiver

排除标准

  • 未提供

研究者

发起方
National Institute on Aging (NIA)
申办方类型
Nih

研究点 (30)

Loading locations...

相似试验

Agitation in Alzheimer's Disease | 临床试验